UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): February 20, 2020
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||
(Address and Zip Code of Principal Executive Offices)
(973 ) 254-3560
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading symbol | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On February 20, 2020, Pacira BioSciences, Inc. issued a press release announcing its results for the fourth quarter and full-year ended December 31, 2019. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02 of Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
Exhibit Number | Description | |
99.1 | ||
104 | Cover Page Interactive Data File (Formatted as Inline XBRL) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PACIRA BIOSCIENCES, INC. (REGISTRANT) | |||
Dated: | February 20, 2020 | By: | /s/ KRISTEN WILLIAMS |
Kristen Williams | |||
Chief Administrative Officer and Secretary | |||
NEWS RELEASE
FOR IMMEDIATE RELEASE
Pacira Reports Record Fourth Quarter and Full-Year Revenues
— Full-year 2019 revenue increases 25 percent to $421 million versus 2018 —
— Total 2020 revenue guidance of between $485 million and $500 million —
— Anesthesia-driven regional approaches are expanding and driving strong EXPAREL growth —
— Conference call today at 8:30 a.m. ET —
PARSIPPANY, N.J., February 20, 2020 - Pacira BioSciences, Inc. (Nasdaq: PCRX) today reported financial results for the fourth quarter and full-year of 2019 and provided 2020 financial guidance.
“By every measure, 2019 was an outstanding year for Pacira. We are delighted to report record revenues for EXPAREL® with our sixth consecutive quarter of more than 20 percent growth,” said Dave Stack, chairman and chief executive officer of Pacira BioSciences. “Demand has continued to mount within the anesthesia community as EXPAREL-based nerve and field blocks take hold as institutional protocol. Additionally, we enhanced our non-opioid pain management product portfolio with the addition of iovera°® and we are seeing great interest from the marketplace around this innovative system.”
“Looking forward, we intend to capitalize on this momentum with robust topline growth that will drive substantial operating leverage and cash flow, providing significant financial flexibility to invest in future growth opportunities. Our mission for 2020 remains steadfast as we continue to propel our global leadership in non-opioid pain management and deliver multiple milestones, including the publication of new data in C-section, label-expansion initiatives for pediatrics and lower extremity nerve block, and the advancement of regulatory activities in Europe, Canada, and China,” added Mr. Stack.
2019 Full-Year and Fourth Quarter Financial Highlights
• | Full-year revenues of $421.0 million and fourth quarter revenues of $122.4 million. |
• | Full-year EXPAREL® (bupivacaine liposome injectable suspension) net product sales of $407.9 million and fourth quarter EXPAREL net product sales of $116.9 million. |
• | Full-year iovera° net product sales were $7.9 million and fourth quarter iovera° net product sales of $3.2 million. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company. |
• | Full-year GAAP net loss of $11.0 million or $0.27 per share (basic and diluted). |
• | Full-year non-GAAP net income of $70.7 million or $1.67 per diluted share. |
• | Fourth quarter GAAP net loss of $4.9 million or $0.12 per share (basic and diluted). |
• | Fourth quarter non-GAAP net income of $23.8 million or $0.56 per diluted share. |
Recent Highlights
• | Launch of national regional anesthesia training initiative with Envision Physician Services. |
In January 2020, Pacira announced a collaboration with Envision Physician Services to train anesthesiology clinicians on ultrasound-guided regional anesthesia techniques utilizing long-acting local anesthetics like EXPAREL via a series of interactive workshops held across the country. The program supports the ongoing efforts by both organizations to advance the delivery of high-quality, patient-centered care.
• | EXPAREL achieves primary and key secondary endpoints in Phase 4 CHOICE study in cesarean section patients. In January 2020, Pacira announced that its Phase 4 study of EXPAREL in patients undergoing Cesarean section achieved its primary endpoint with a statistically significant reduction in total postsurgical opioid consumption while maintaining pain scores through 72 hours (P≤0.001). EXPAREL demonstrated statistical significance for the key secondary endpoint of a reduction in the incidence and severity of itching for 72 hours after surgery (P≤0.05). Full study results will be submitted for publication in the peer-reviewed medical literature later this year. |
• | Phase 3 PLAY study of EXPAREL in pediatric patients achieves positive results. In December 2019, Pacira announced positive results from its Phase 3 PLAY study of EXPAREL administered as a single-dose infiltration in pediatric patients undergoing spinal or cardiac surgeries. Overall findings were consistent with the pharmacokinetic and safety profiles for adult patients with no safety concerns identified at a dose of 4 mg/kg. These results will provide the foundation for the company’s supplemental New Drug Application submission in the first half of 2020 to the U.S. Food and Drug Administration (FDA) seeking expansion of the EXPAREL label to include children aged six and over. |
Fourth Quarter 2019 Financial Results
• | Total revenues were $122.4 million in the fourth quarter of 2019, a 29% increase over the $95.1 million reported for the fourth quarter of 2018. |
• | EXPAREL net product sales were $116.9 million in the fourth quarter of 2019, a 24% increase over the $94.4 million reported for the fourth quarter of 2018. |
• | Fourth quarter iovera° net product sales were $3.2 million. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company. |
• | Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $1.7 million in the fourth quarter of 2019, compared to $0.3 million in 2018. |
• | Fourth quarter royalty revenue was $0.6 million compared to $0.4 million in 2018. |
• | Total operating expenses were $120.7 million in the fourth quarter of 2019, compared to $82.9 million in the fourth quarter of 2018. |
• | Research and development (R&D) expenses were $19.7 million in the fourth quarter of 2019, compared to $14.2 million in the fourth quarter of 2018. The company’s R&D expenses include $8.7 million and $6.5 million of product development and manufacturing capacity expansion costs in the fourth quarters of 2019 and 2018, respectively. |
• | Selling, general and administrative (SG&A) expenses were $54.2 million in the fourth quarter of 2019, compared to $44.6 million in the fourth quarter of 2018. |
• | GAAP net loss was $4.9 million, or $0.12 per share (basic and diluted) in the fourth quarter of 2019, compared to GAAP net income of $8.3 million, or $0.20 per share (basic and diluted), in the fourth quarter of 2018. |
• | Non-GAAP net income was $23.8 million, or $0.57 per share (basic) and $0.56 per share (diluted), in the fourth quarter of 2019, compared to non-GAAP net income of $19.8 million, or $0.48 per share (basic) and $0.47 per share (diluted), in the fourth quarter of 2018. |
• | Pacira had 41.8 million basic weighted average shares of common stock outstanding in the fourth quarter of 2019. |
• | For non-GAAP measures, Pacira had 42.6 million diluted weighted average shares of common stock outstanding in the fourth quarter of 2019. |
Full-Year 2019 Financial Results
• | Total revenues were $421.0 million in 2019, a 25% increase over the $337.3 million reported in 2018. |
• | EXPAREL net product sales were $407.9 million in 2019, a 23% increase over the $331.1 million reported in 2018. |
• | Full-year iovera° net product sales were $7.9 million. Pacira began recognizing sales of iovera° in April 2019 after completing its acquisition of MyoScience, Inc., a privately held medical technology company. |
• | Sales of bupivacaine liposome injectable suspension to a third-party licensee for use in veterinary practice were $3.2 million in 2019, compared to $1.3 million in 2018. |
• | Full-year royalty revenue was $2.1 million compared to $1.9 million in 2018. |
• | Total operating expenses were $410.5 million in 2019, compared to $321.4 million in 2018. |
• | Research and development (R&D) expenses were $72.1 million in 2019, compared to $55.7 million in 2018. The company’s R&D expenses include $29.7 million and $28.5 million of product development and manufacturing capacity expansion costs in 2019 and 2018, respectively. |
• | Selling, general and administrative (SG&A) expenses were $200.8 million in 2019, compared to $177.3 million in 2018. |
• | GAAP net loss was $11.0 million, or $0.27 per share (basic and diluted) in 2019, compared to a GAAP net loss of $0.5 million, or $0.01 per share (basic and diluted) in 2018. |
• | Non-GAAP net income was $70.7 million, or $1.70 per share (basic) and $1.67 per share (diluted), in 2019, compared to non-GAAP net income of $43.5 million, or $1.06 per share (basic) and $1.04 per share (diluted), in 2018. |
• | Pacira ended 2019 with cash, cash equivalents, short-term and long-term investments (“cash”) of $356.7 million. Cash provided by operations was $70.5 million in 2019, compared to $48.9 million in 2018. |
• | Pacira had 41.5 million basic weighted average shares of common stock outstanding in 2019. |
• | For non-GAAP measures, Pacira had 42.4 million diluted weighted average shares of common stock outstanding in 2019. |
2020 Outlook
Pacira announces its full-year 2020 financial guidance as follows. Pacira expects:
• | Total revenues to be between $485 million and $500 million; |
• | EXPAREL net product sales to be between $465 million and $475 million; |
• | iovera° net product sales to be between $15 million and $20 million; |
• | Non-GAAP gross margins to be between 76% and 78%; |
• | Non-GAAP research and development (R&D) expense to be between $60 million to $70 million; |
• | Non-GAAP selling, general and administrative (SG&A) expense to be between $180 million and $190 million; and |
• | Stock-based compensation to be between $35 million and $40 million. |
See “Non-GAAP Financial Information” and “Reconciliations of GAAP to Non-GAAP 2020 Financial Guidance” below.
Today’s Conference Call and Webcast Reminder
The Pacira management team will host a conference call to discuss the company’s financial results and recent developments today, Thursday, February 20, 2020, at 8:30 a.m. ET. To participate in the conference call, dial 1-877-845-0779 and provide the passcode 8765839. International callers may dial 1-720-545-0035 and use the same passcode. In addition, a live audio of the conference call will be available as a webcast. Interested parties can access the event through the “Events” page on the Pacira website at investor.pacira.com.
For those unable to participate in the live call, a replay will be available at 1-855-859-2056 (domestic) or 1-404-537-3406 (international) using the passcode 8765839. The replay of the call will be available for one week from the date of the live call. The webcast will be available on the Pacira website for approximately two weeks following the call.
Non-GAAP Financial Information
This press release contains financial measures that do not comply with U.S. generally accepted accounting principles (GAAP), such as non-GAAP net income, non-GAAP net income per share, non-GAAP cost of goods sold, non-GAAP gross margins, non-GAAP research and development (R&D) expense and non-GAAP selling, general and administrative (SG&A) expense, because such measures exclude milestone revenue; acquisition-related charges, product discontinuation costs and other expense; stock-based compensation; amortization of debt discount; amortization of acquired intangible assets; an income tax benefit and step-up in basis of inventory in connection with the acquisition of MyoScience, Inc.; and loss on investment and other non-operating income.
These measures supplement Pacira’s financial results prepared in accordance with GAAP. Pacira management uses these measures to better analyze its financial results, estimate its future cost of goods sold, gross margins, R&D expense and SG&A expense outlook for 2020 and to help make managerial decisions. In management’s opinion, these non-GAAP measures are useful to investors and other users of our financial statements by providing greater transparency into the operating performance at Pacira and its future outlook. Such measures should not be deemed to be an alternative to GAAP requirements or a measure of liquidity for Pacira. Non-GAAP measures are also unlikely to be comparable with non-GAAP disclosures released by other companies. See the tables below for a reconciliation of GAAP to non-GAAP
measures, and a reconciliation of our GAAP to non-GAAP 2020 financial guidance for gross margins, R&D expense and SG&A expense.
About Pacira BioSciences
Pacira BioSciences, Inc. (Nasdaq: PCRX) is a leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for health care practitioners and their patients. The company’s long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera°® system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
About EXPAREL
EXPAREL (bupivacaine liposome injectable suspension) is indicated for single-dose infiltration in adults to produce postsurgical local analgesia and as an interscalene brachial plexus nerve block to produce postsurgical regional analgesia. Safety and efficacy have not been established in other nerve blocks. The product combines bupivacaine with DepoFoam, a proven product delivery technology that delivers medication over a desired time period. EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting. By utilizing the DepoFoam platform, a single dose of EXPAREL delivers bupivacaine over time, providing significant reductions in cumulative pain scores with up to a 78 percent decrease in opioid consumption; the clinical benefit of the opioid reduction was not demonstrated. Additional information is available at www.EXPAREL.com.
Important Safety Information for Patients
EXPAREL should not be used in obstetrical paracervical block anesthesia. In studies where EXPAREL was injected into the wound, the most common side effects were nausea, constipation, and vomiting. In studies where EXPAREL was injected near a nerve, the most common side effects were nausea, fever, and constipation. EXPAREL is not recommended to be used in patients younger than 18 years old or in pregnant women. Tell your healthcare provider if you have liver disease, since this may affect how the active ingredient (bupivacaine) in EXPAREL is eliminated from your body. EXPAREL should not be injected into the spine, joints, or veins. The active ingredient in EXPAREL: can affect your nervous system and your cardiovascular system; may cause an allergic reaction; may cause damage if injected into your joints.
About iovera°
The iovera° system is used to destroy tissue during surgical procedures by applying freezing cold. It can also be used to produce lesions in peripheral nervous tissue by the application of cold to the selected site for the blocking of pain. It is also indicated for the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days. In one study, the majority of the patients suffering from osteoarthritis of the knee experienced pain and system relief beyond 150 days.1 The iovera° system’s “1×90” Smart Tip configuration (indicating one needle which is 90 mm long) can also facilitate target nerve location by conducting electrical nerve stimulation from a separate nerve stimulator. The iovera° system is not indicated for treatment of central nervous system tissue.
1Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10.
Important Safety Information
The iovera° system is contraindicated for use in patients with the following: Cryoglobulinemia; Paroxysmal cold hemoglobinuria; cold urticaria; Raynaud’s disease; open and/or infected wounds at or near the treatment line. Potential complications: As with any surgical treatment that uses needle-based therapy, there is potential for temporary site-specific reactions, including but not limited to: bruising (ecchymosis); swelling (edema); inflammation and/or redness (erythema); pain and/or tenderness; altered sensation (localized dysesthesia). Typically, these reactions resolve with no physician intervention. Patients may help the healing process by applying ice packs to the affected sites, and by taking over-the-counter analgesics.
Forward-Looking Statements
Any statements in this press release about the company’s future expectations, plans, outlook, projections and prospects, and other statements containing the words “believes,” “anticipates,” “plans,” “estimates,” “expects,” “intends,” “may,” “will,” “would,” “could,” “can” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks relating to: the success of the company’s sales and manufacturing efforts in support of the commercialization of EXPAREL; the rate and degree of market acceptance of EXPAREL; the size and growth of the potential markets for EXPAREL and the company’s ability to serve those markets; the company’s plans to expand the use of EXPAREL to additional indications and opportunities, and the timing and success of any related clinical trials; the ability to realize anticipated benefits and synergies from the acquisition of MyoScience; the ability to successfully integrate iovera° and any other future acquisitions into the company’s existing business; the commercial success of iovera° and other factors discussed in the “Risk Factors” of the company’s most recent Annual Report on Form 10-K and in other filings that the company periodically makes with the SEC. In addition, the forward-looking statements included in this press release represent the company’s views as of the date of this press release. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such the company anticipates that subsequent events and developments will cause its views to change. However, while the company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
###
Investor Contact:
Susan Mesco, (973) 451-4030
susan.mesco@pacira.com
Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
aschneider@coynepr.com
(Tables to Follow)
Pacira BioSciences, Inc.
Condensed Consolidated Balance Sheets
(in thousands)
(unaudited)
December 31, 2019 | December 31, 2018 | ||||||
ASSETS | |||||||
Current assets: | |||||||
Cash, cash equivalents and short-term investments | $ | 291,950 | $ | 383,454 | |||
Accounts receivable, net | 47,530 | 38,000 | |||||
Inventories, net | 58,296 | 48,569 | |||||
Prepaid expenses and other current assets | 10,781 | 7,946 | |||||
Total current assets | 408,557 | 477,969 | |||||
Long-term investments | 64,798 | 25,871 | |||||
Fixed assets, net | 104,681 | 108,670 | |||||
Right-of-use assets, net | 38,124 | — | |||||
Goodwill | 99,547 | 62,040 | |||||
Intangible assets, net | 104,387 | — | |||||
Equity investment and other assets | 10,971 | 14,803 | |||||
Total assets | $ | 831,065 | $ | 689,353 | |||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 12,799 | $ | 14,368 | |||
Accrued expenses | 70,427 | 45,865 | |||||
Lease liabilities | 4,935 | — | |||||
Convertible senior notes (1) | — | 338 | |||||
Contingent consideration | 18,179 | — | |||||
Income taxes payable | 1,333 | 90 | |||||
Total current liabilities | 107,673 | 60,661 | |||||
Convertible senior notes (2) | 306,045 | 290,592 | |||||
Lease liabilities | 40,938 | — | |||||
Contingent consideration | 19,963 | — | |||||
Other liabilities | 1,502 | 16,874 | |||||
Total stockholders’ equity | 354,944 | 321,226 | |||||
Total liabilities and stockholders’ equity | $ | 831,065 | $ | 689,353 | |||
(1) Relates to our 3.25% convertible senior notes due 2019 that matured on February 1, 2019.
(2) Relates to our 2.375% convertible senior notes due 2022 that are not currently convertible.
Pacira BioSciences, Inc.
Consolidated Statements of Operations
(in thousands, except per share amounts)
(unaudited)
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
Net product sales: | |||||||||||||||
EXPAREL | $ | 116,939 | $ | 94,422 | $ | 407,877 | $ | 331,112 | |||||||
Bupivacaine liposome injectable suspension | 1,685 | 293 | 3,153 | 1,315 | |||||||||||
Total EXPAREL / bupivacaine liposome injectable suspension net product sales | 118,624 | 94,715 | 411,030 | 332,427 | |||||||||||
iovera° | 3,221 | — | 7,896 | — | |||||||||||
Total net product sales | 121,845 | 94,715 | 418,926 | 332,427 | |||||||||||
Collaborative licensing and milestone revenue | — | — | — | 3,000 | |||||||||||
Royalty revenue | 579 | 400 | 2,100 | 1,850 | |||||||||||
Total revenues | 122,424 | 95,115 | 421,026 | 337,277 | |||||||||||
Operating expenses: | |||||||||||||||
Cost of goods sold | 31,904 | 23,979 | 106,712 | 86,845 | |||||||||||
Research and development | 19,653 | 14,174 | 72,119 | 55,688 | |||||||||||
Selling, general and administrative | 54,223 | 44,647 | 200,782 | 177,265 | |||||||||||
Amortization of acquired intangible assets | 1,967 | — | 5,703 | — | |||||||||||
Acquisition-related charges, product discontinuation and other | 12,965 | 53 | 25,230 | 1,564 | |||||||||||
Total operating expenses | 120,712 | 82,853 | 410,546 | 321,362 | |||||||||||
Income from operations | 1,712 | 12,262 | 10,480 | 15,915 | |||||||||||
Other income (expense): | |||||||||||||||
Interest income | 1,667 | 2,004 | 7,376 | 6,497 | |||||||||||
Interest expense | (5,997 | ) | (5,753 | ) | (23,628 | ) | (21,949 | ) | |||||||
Other, net | (923 | ) | (191 | ) | (4,976 | ) | (888 | ) | |||||||
Total other expense, net | (5,253 | ) | (3,940 | ) | (21,228 | ) | (16,340 | ) | |||||||
Income (loss) before income taxes | (3,541 | ) | 8,322 | (10,748 | ) | (425 | ) | ||||||||
Income tax expense | (1,347 | ) | (37 | ) | (268 | ) | (46 | ) | |||||||
Net income (loss) | $ | (4,888 | ) | $ | 8,285 | $ | (11,016 | ) | $ | (471 | ) | ||||
Net income (loss) per share: | |||||||||||||||
Basic and diluted net income (loss) per common share | $ | (0.12 | ) | $ | 0.20 | $ | (0.27 | ) | $ | (0.01 | ) | ||||
Weighted average common shares outstanding: | |||||||||||||||
Basic | 41,784 | 41,148 | 41,513 | 40,911 | |||||||||||
Diluted | 41,784 | 42,219 | 41,513 | 40,911 | |||||||||||
Pacira BioSciences, Inc.
Reconciliation of GAAP to Non-GAAP Financial Information
(in thousands, except per share amounts)
(unaudited)
Three Months Ended | Year Ended | ||||||||||||||
December 31, | December 31, | ||||||||||||||
2019 | 2018 | 2019 | 2018 | ||||||||||||
GAAP net income (loss) | $ | (4,888 | ) | $ | 8,285 | $ | (11,016 | ) | $ | (471 | ) | ||||
Non-GAAP adjustments: | |||||||||||||||
Milestone revenue (1) | — | — | — | (3,000 | ) | ||||||||||
Acquisition-related charges, product discontinuation and other | 12,965 | 53 | 25,230 | 1,564 | |||||||||||
Stock-based compensation | 9,189 | 8,186 | 33,650 | 31,725 | |||||||||||
Amortization of debt discount | 3,530 | 3,286 | 13,746 | 12,799 | |||||||||||
Amortization of acquired intangible assets | 1,967 | — | 5,703 | — | |||||||||||
Income tax benefit in connection with acquisition | — | — | (1,828 | ) | — | ||||||||||
Recognition of step-up basis in inventory from acquisition | — | — | 220 | — | |||||||||||
Loss on investment and other non-operating income, net | 1,023 | — | 4,981 | 854 | |||||||||||
Total Non-GAAP adjustments | 28,674 | 11,525 | 81,702 | 43,942 | |||||||||||
Non-GAAP net income | $ | 23,786 | $ | 19,810 | $ | 70,686 | $ | 43,471 | |||||||
GAAP basic and diluted net income (loss) per common share | $ | (0.12 | ) | $ | 0.20 | $ | (0.27 | ) | $ | (0.01 | ) | ||||
Non-GAAP basic net income per common share | $ | 0.57 | $ | 0.48 | $ | 1.70 | $ | 1.06 | |||||||
Non-GAAP diluted net income per common share | $ | 0.56 | $ | 0.47 | $ | 1.67 | $ | 1.04 | |||||||
Weighted average common shares outstanding - basic | 41,784 | 41,148 | 41,513 | 40,911 | |||||||||||
Weighted average common shares outstanding - diluted | 42,612 | 42,219 | 42,370 | 41,869 | |||||||||||
Cost of goods sold reconciliation: | |||||||||||||||
GAAP cost of goods sold | $ | 31,904 | $ | 23,979 | $ | 106,712 | $ | 86,845 | |||||||
Stock-based compensation | (1,174 | ) | (1,047 | ) | (4,665 | ) | (4,478 | ) | |||||||
Recognition of step-up basis in inventory from acquisition | — | — | (220 | ) | — | ||||||||||
Non-GAAP cost of goods sold | $ | 30,730 | $ | 22,932 | $ | 101,827 | $ | 82,367 | |||||||
Research and development reconciliation: | |||||||||||||||
GAAP research and development | $ | 19,653 | $ | 14,174 | $ | 72,119 | $ | 55,688 | |||||||
Stock-based compensation | (1,342 | ) | (1,164 | ) | (5,114 | ) | (3,934 | ) | |||||||
Non-GAAP research and development | $ | 18,311 | $ | 13,010 | $ | 67,005 | $ | 51,754 | |||||||
Selling, general and administrative reconciliation: | |||||||||||||||
GAAP selling, general and administrative | $ | 54,223 | $ | 44,647 | $ | 200,782 | $ | 177,265 | |||||||
Stock-based compensation | (6,672 | ) | (5,975 | ) | (23,871 | ) | (23,313 | ) | |||||||
Non-GAAP selling, general and administrative | $ | 47,551 | $ | 38,672 | $ | 176,911 | $ | 153,952 | |||||||
(1) Represents a $3.0 million upfront payment earned under our agreement with Nuance Biotech Co. Ltd. for the development and commercialization of EXPAREL in China.
Pacira BioSciences, Inc.
Reconciliation of GAAP to Non-GAAP 2020 Financial Guidance
(dollars in millions)
GAAP to Non-GAAP Guidance | GAAP | Stock-Based Compensation | Non-GAAP | |||
Total revenues | $485 to $500 | — | — | |||
EXPAREL net product sales | $465 to $475 | — | — | |||
iovera° net product sales | $15 to $20 | — | — | |||
Gross margin | 75% to 77% | Approx. 1% | 76% to 78% | |||
Research and development expense | $64 to $76 | $4 to $6 | $60 to $70 | |||
Selling, general and administrative expense | $207 to $219 | $27 to $29 | $180 to $190 | |||
Stock-based compensation | $35 to $40 | — | — | |||